Artivion, Inc.
44.99-0.27 (-0.6%)
Oct 29, 4:00:02 PM EDT · NYSE · AORT · USD
Key Stats
Market Cap
2.12BP/E (TTM)
-Basic EPS (TTM)
-0.43Dividend Yield
0%Recent Filings
8-K
Artivion buys Austin facilities
Artivion inked deals on September 26, 2025, to buy two Austin properties for $20.5 million in cash, securing its On-X manufacturing site while expanding capacity amid rising needs. The 1300 Property, 75,000 square feet, hosts current operations; the adjacent 1200 Property adds 87,000 square feet for growth. Closings follow feasibility periods of 45 and 100 days. Deals hinge on inspections.
8-K
Artivion, Inc. announces a Second Amendment to its Credit Agreement, extending maturities to 2031, lowering interest rates, and securing $150M in new financing for strategic growth.
Artivion, Inc. enters into a Second Amendment to its Credit and Guaranty Agreement, extending the maturity of existing term loans and revolving credit facilities from January 18, 2030 to January 18, 2031, reducing interest rate margins, and adding a new $150 million delayed draw term loan facility available until September 13, 2027 for acquisitions, real estate, and capital expenditures.
8-K
Berry named COO; Stanton retiring
Artivion appointed Lance A. Berry as Chief Operating Officer effective August 11, 2025, alongside his ongoing CFO and Treasurer roles, leveraging his prior experience at Wright Medical. This bolsters operational oversight amid Dr. Marshall Stanton's planned retirement from Senior VP of Clinical Research and Chief Medical Officer on March 31, 2026, with no disagreements noted. Berry's package includes $540,000 base salary and 70% target bonus. Stanton will offer transition advice post-retirement.
10-Q
Q2 FY2025 results
Artivion posted Q2 revenues of $113.0M, up 15% y/y from $98.0M, fueled by 19% growth in products like aortic stent grafts (24% y/y) and On-X valves (24% y/y), while preservation services edged up 3% y/y on backlog releases from last year's cyber incident. Gross margin held steady at 65%, but operating income climbed to $8.4M from $6.5M y/y, thanks to volume gains and pricing, though higher G&A expenses from sales investments and stock comp tempered the lift. Net income flipped to $1.3M profit from a $2.1M loss, with diluted EPS at $0.03; YTD net income of $0.8M aligns with 44.5M diluted shares. Cash stayed flat at $53.5M amid $1.9M operating outflow, but debt dropped to $220.5M after settling $100M convertible notes via stock issuance, leaving $30M revolver availability under covenants met. Momentum builds in key segments. Yet regulatory hurdles for tissues loom large.
8-K
Artivion Q2 revenue jumps 15%
Artivion reported Q2 2025 revenue of $113.0 million, up 15% from $98.0 million in Q2 2024, fueled by 24% growth in On-X valves and aortic stent grafts. Adjusted EBITDA surged 33% to $24.8 million, while the company exchanged $99.5 million in convertible notes for stock, retiring the full $100 million due July 1, 2025. FDA IDE approval launched the ARTIZEN trial for Arcevo LSA aortic arch replacement. Artivion raised full-year guidance to $435–$443 million revenue and $86–$91 million adjusted EBITDA. Momentum builds.
ATRC
AtriCure, Inc.
35.44-1.01
AVNS
Avanos Medical, Inc.
11.43-0.15
BSX
Boston Scientific Corporation
100.30-0.67
BVS
Bioventus Inc.
6.77-0.17
ELUT
Elutia, Inc.
0.90+0.01
ENOV
Enovis Corporation
31.99-0.87
EW
Edwards Lifesciences Corporatio
82.69+0.50
MDNC
MEDINOTEC INC
5.00+0.00
NVNO
enVVeno Medical Corporation
0.72+0.00
TELA
TELA Bio, Inc.
1.32-0.12